APA (7th ed.) Citation

ÉJF, P. d. M., RT, C., FC, B., JA, d. S. M., FF, M., MAALDS, A., . . . EG, K. (2025). Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil. Vaccine, 52, 126680. https://doi.org/10.1016/j.vaccine.2024.126680

Chicago Style (17th ed.) Citation

ÉJF, Peixoto de Miranda, et al. "Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Results of a Randomized Vaccine-controlled Phase I ADAPTCOV Trial in Brazil." Vaccine 52 (2025): 126680. https://doi.org/10.1016/j.vaccine.2024.126680.

MLA (9th ed.) Citation

ÉJF, Peixoto de Miranda, et al. "Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Results of a Randomized Vaccine-controlled Phase I ADAPTCOV Trial in Brazil." Vaccine, vol. 52, 2025, p. 126680, https://doi.org/10.1016/j.vaccine.2024.126680.